Provided by Tiger Fintech (Singapore) Pte. Ltd.

Savara Inc

2.41
+0.12005.24%
Post-market: 2.420.0107+0.44%19:16 EDT
Volume:1.44M
Turnover:3.42M
Market Cap:416.54M
PE:-4.87
High:2.42
Open:2.29
Low:2.28
Close:2.29
Loading ...

Savara Inc. Announces New Inducement Awards for Employees Under 2021 Equity Incentive Plan

Reuters
·
19 Jul

Master Tec Group Enters MoU With Senari Synergy Sdn. Bhd

Reuters
·
15 Jul

INDIA STOCKS-Indian markets set for muted open as Middle East tensions spur caution

Reuters
·
20 Jun

INDIA STOCKS-Indian benchmarks dip as Trump's Tehran evacuation call unsettles investors

Reuters
·
17 Jun

Savara Inc. Conducted Annual Stockholders Meeting

Reuters
·
07 Jun

Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating

MT Newswires Live
·
02 Jun

HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6

MT Newswires Live
·
29 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Savara (SVRA) and Intellia Therapeutics (NTLA)

TIPRANKS
·
29 May

Savara downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
29 May

Savara Is Maintained at Overweight by Wells Fargo

Dow Jones
·
28 May

Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA)

TIPRANKS
·
28 May

Savara Inc. Unveils Presentation on New Therapies for Rare Respiratory Diseases

Reuters
·
27 May

Savara Shares Down 25.3% at $2.12 After FDA Refuses to Accept Co's Application for Lung Disease Therapy

THOMSON REUTERS
·
27 May

Savara Shares Slide After FDA Declines Drug Application

Dow Jones
·
27 May

Savara Shares Down 34.1% at $1.89 Premarket After FDA Refuses to Accept Co's Application for Lung Disease Therapy

THOMSON REUTERS
·
27 May

Savara Inc. Receives FDA Refusal to File Letter for MOLBREEVI BLA, Plans to Resubmit in Q4 2025

Reuters
·
27 May

Savara Inc - FDA Requests Additional Cmc Data for Molbreevi Bla

THOMSON REUTERS
·
27 May

Savara Inc - to Request Type a Meeting With FDA Within 30 Days

THOMSON REUTERS
·
27 May

Savara Inc: Expects to Resubmit Our Bla in Q4 of 2025

THOMSON REUTERS
·
27 May

Savara Receives Refusal to File (Rtf) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (Bla) for Molbreevi* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS
·
27 May